Experienced in Protein C Deficiency

Dr. Ara Metjian

Hematology
Duke Health Integrated Practice Inc
234 Crooked Creek Pkwy, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Protein C Deficiency
Duke Health Integrated Practice Inc
234 Crooked Creek Pkwy, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ara Metjian is a Hematologist in Durham, North Carolina. Dr. Metjian is rated as an Experienced provider by MediFind in the treatment of Protein C Deficiency. His top areas of expertise are Purpura, Thrombocytopenia, Blood Clots, and Thrombotic Thrombocytopenic Purpura.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke Regional Hospital
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 9 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
234 Crooked Creek Pkwy, Durham, NC 27713
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Enrollment Status: Recruiting
Publish Date: April 22, 2025
Intervention Type: Biological
Study Drug: TAK-755
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Biological
Study Drug: BAX930
Study Phase: Phase 3
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: Apixaban, Warfarin
Study Phase: Phase 4
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
View 4 Less Clinical Trials

27 Total Publications

Proteomics of arterial thrombi in acute limb ischemia.
Proteomics of arterial thrombi in acute limb ischemia.
Journal: Journal of thrombosis and thrombolysis
Published: May 26, 2025
Similar Doctors
Advanced in Protein C Deficiency
Dr. Alan D. Kritz
Hematology Oncology | Hematology | Oncology
Advanced in Protein C Deficiency
Dr. Alan D. Kritz
Hematology Oncology | Hematology | Oncology

Rex Hospital Inc

4420 Lake Boone Trl, 
Raleigh, NC 
 (14.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alan Kritz is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Kritz is rated as a Distinguished provider by MediFind in the treatment of Protein C Deficiency. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Multiple Myeloma, and Paget Disease of the Breast. Dr. Kritz is currently accepting new patients.

Soheir S. Adam
Experienced in Protein C Deficiency
Dr. Soheir S. Adam
Hematology
Experienced in Protein C Deficiency
Dr. Soheir S. Adam
Hematology

Duke Adult Comprehensive Sickle Cell Center - Clinic 2N

40 Duke Medicine Cir, 
Durham, NC 
 (6.4 miles away)
919-684-6464
Experience:
43+ years
Languages Spoken:
English, Arabic, French
See accepted insurances
Offers Telehealth

Soheir Adam is a Hematologist in Durham, North Carolina. Dr. Adam has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Protein C Deficiency. Her top areas of expertise are Sickle Cell Disease, Pulmonary Embolism, Anemia, and Hemoglobin SC Disease.

Experienced in Protein C Deficiency
Dr. George H. Sanders
Hematology Oncology | Hematology | Oncology
Experienced in Protein C Deficiency
Dr. George H. Sanders
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

601 N Elm St, 
High Point, NC 
 (60.6 miles away)
336-716-2734
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

George Sanders is a Hematologist Oncology specialist and a Hematologist in High Point, North Carolina. Dr. Sanders is rated as a Distinguished provider by MediFind in the treatment of Protein C Deficiency. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast. Dr. Sanders is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Metjian's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile